CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 25 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $66,000 | -87.0% | 82,765 | -84.4% | 0.00% | -100.0% |
| Q2 2018 | $508,000 | +1351.4% | 530,187 | +3153.9% | 0.00% | – |
| Q3 2017 | $35,000 | -82.9% | 16,294 | -36.9% | 0.00% | – |
| Q4 2015 | $205,000 | -60.3% | 25,830 | -59.6% | 0.00% | -100.0% |
| Q3 2015 | $517,000 | -43.4% | 63,957 | -14.5% | 0.00% | -50.0% |
| Q2 2015 | $913,000 | – | 74,791 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $23,118,000 | 12.93% |
| Clarus Ventures, LLC | 2,752,488 | $22,268,000 | 12.81% |
| Camber Capital Management LP | 1,000,000 | $8,090,000 | 0.69% |
| Rhenman & Partners Asset Management AB | 300,427 | $2,430,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 327,476 | $2,595,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 628,482 | $5,084,000 | 0.20% |
| Spark Investment Management LLC | 32,500 | $263,000 | 0.03% |
| Tower Research Capital LLC (TRC) | 10,764 | $87,000 | 0.01% |
| VANGUARD GROUP INC | 4,732,472 | $168,937,000 | 0.01% |
| Alyeska Investment Group, L.P. | 40,220 | $325,000 | 0.00% |